

Mirtazapine Orally Disintegrating Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/01/2017
3.4	06/12/2017	50205-00008	Date of first issue: 01/23/2015

SECTION 1. IDENTIFICATION

Product name : Mirtazapine Orally Disintegrating Tablet Formulation

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc

Address : 2000 Galloping Hill Road
Kenilworth - New Jersey - USA 1685

Telephone : 908-740-4000

Telefax : 908-735-1496

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with 29 CFR 1910.1200

Combustible dust

Acute toxicity (Oral) : Category 4

Reproductive toxicity : Category 2

Specific target organ
systemic toxicity - repeated
exposure (Oral) : Category 2 (Nervous system)

GHS label elements

Hazard pictograms :



Signal Word : Warning

Hazard Statements : If small particles are generated during further processing, handling or by other means, may form combustible dust concentrations in air.
H302 Harmful if swallowed.
H361fd Suspected of damaging fertility. Suspected of damaging the unborn child.
H373 May cause damage to organs (Nervous system) through

**Mirtazapine Orally Disintegrating Tablet For-
mulation**

Version	Revision Date:	SDS Number:	Date of last issue: 05/01/2017
3.4	06/12/2017	50205-00008	Date of first issue: 01/23/2015

prolonged or repeated exposure if swallowed.

Precautionary Statements

:

Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read and understood.

P260 Do not breathe dust.

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.

P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth.

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**Substance / Mixture**

:

Mixture**Hazardous ingredients**

Chemical name	CAS-No.	Concentration (% w/w)
(+/-)-1,2,3,4,10,14b-hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine	85650-52-8	>= 20 - < 30
Citric acid	77-92-9	>= 1 - < 5
Cellulose	9004-34-6	>= 1 - < 5
Magnesium stearate	557-04-0	>= 1 - < 5

SECTION 4. FIRST AID MEASURES**General advice**

:

In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled

:

If inhaled, remove to fresh air.
Get medical attention.

**Mirtazapine Orally Disintegrating Tablet For-
mulation**

Version	Revision Date:	SDS Number:	Date of last issue: 05/01/2017
3.4	06/12/2017	50205-00008	Date of first issue: 01/23/2015

- | | | |
|---|---|---|
| In case of skin contact | : | In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse. |
| In case of eye contact | : | If in eyes, rinse well with water.
Get medical attention if irritation develops and persists. |
| If swallowed | : | If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.
Never give anything by mouth to an unconscious person. |
| Most important symptoms and effects, both acute and delayed | : | Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.
Harmful if swallowed.
Suspected of damaging fertility. Suspected of damaging the unborn child.
May cause damage to organs through prolonged or repeated exposure if swallowed. |
| Protection of first-aiders | : | First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists. |
| Notes to physician | : | Treat symptomatically and supportively. |

SECTION 5. FIRE-FIGHTING MEASURES

- | | | |
|---------------------------------------|---|---|
| Suitable extinguishing media | : | Water spray
Alcohol-resistant foam
Carbon dioxide (CO ₂)
Dry chemical |
| Unsuitable extinguishing media | : | None known. |
| Specific hazards during fire fighting | : | Exposure to combustion products may be a hazard to health. |
| Hazardous combustion products | : | Carbon oxides
Nitrogen oxides (NO _x)
Metal oxides |
| Specific extinguishing methods | : | Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so. |

**Mirtazapine Orally Disintegrating Tablet For-
mulation**

Version	Revision Date:	SDS Number:	Date of last issue: 05/01/2017
3.4	06/12/2017	50205-00008	Date of first issue: 01/23/2015

Evacuate area.

Special protective equipment : In the event of fire, wear self-contained breathing apparatus.
for fire-fighters Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions : Discharge into the environment must be avoided.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety practice.
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment.

Mirtazapine Orally Disintegrating Tablet For- mulation

Version 3.4 Revision Date: 06/12/2017 SDS Number: 50205-00008 Date of last issue: 05/01/2017
Date of first issue: 01/23/2015

- Conditions for safe storage : Keep in properly labeled containers.
Store locked up.
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Ingredients	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
(+/-)-1,2,3,4,10,14b-hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine	85650-52-8	TWA	25 µg/m ³	Merck
		Wipe limit	250 µg/100 cm ²	Merck
Cellulose	9004-34-6	TWA	10 mg/m ³	ACGIH
		TWA (Respirable)	5 mg/m ³	NIOSH REL
		TWA (total)	10 mg/m ³	NIOSH REL
		TWA (total dust)	15 mg/m ³	OSHA Z-1
		TWA (respirable fraction)	5 mg/m ³	OSHA Z-1
Magnesium stearate	557-04-0	TWA	10 mg/m ³	ACGIH

Hazardous components without workplace control parameters

Ingredients	CAS-No.
Citric acid	77-92-9

- Engineering measures** : Ensure adequate ventilation, especially in confined areas.
Minimize workplace exposure concentrations.
Apply measures to prevent dust explosions.
Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).
Dust formation may be relevant in the processing of this product. In addition to substance-specific OELs, general limitations of concentrations of particulates in the air at workplaces have to be considered in workplace risk assessment. Relevant limits include: OSHA PEL for Particulates Not Otherwise Regulated of 15 mg/m³ - total dust, 5 mg/m³ - respirable fraction; and ACGIH TWA for Particles (insoluble or poorly soluble) Not Otherwise Specified of 3 mg/m³ - respirable particles, 10 mg/m³ - inhalable particles.

**Mirtazapine Orally Disintegrating Tablet For-
mulation**

Version	Revision Date:	SDS Number:	Date of last issue: 05/01/2017
3.4	06/12/2017	50205-00008	Date of first issue: 01/23/2015

Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

Hand protection
Material : Chemical-resistant gloves

Remarks : Choose gloves to protect hands against chemicals depending on the concentration specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

Eye protection : Wear the following personal protective equipment:
Safety goggles

Skin and body protection : Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential.
Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).

Hygiene measures : Ensure that eye flushing systems and safety showers are located close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder

Color : No data available

Odor : No information available.

Odor Threshold : No data available

pH : No data available

Mirtazapine Orally Disintegrating Tablet Formulation

Version 3.4	Revision Date: 06/12/2017	SDS Number: 50205-00008	Date of last issue: 05/01/2017 Date of first issue: 01/23/2015
----------------	------------------------------	----------------------------	---

Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, dynamic	:	No data available
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle size	:	No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
------------	---	--

Mirtazapine Orally Disintegrating Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/01/2017
3.4	06/12/2017	50205-00008	Date of first issue: 01/23/2015

Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Dust can form an explosive mixture in air. Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION**Information on likely routes of exposure**

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Harmful if swallowed.

Product:

Acute oral toxicity	:	Acute toxicity estimate: 1,588 mg/kg Method: Calculation method
---------------------	---	--

Ingredients:**(+/-)-1,2,3,4,10,14b-hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Acute oral toxicity	:	LD50 (Rat): 320 - 490 mg/kg
---------------------	---	-----------------------------

Citric acid:

Acute oral toxicity	:	LD50 (Mouse): 5,400 mg/kg
Acute dermal toxicity	:	LD50 (Rat): > 2,000 mg/kg Method: OECD Test Guideline 402 Assessment: The substance or mixture has no acute dermal toxicity

Cellulose:

Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity	:	LC50 (Rat): > 5.8 mg/l Exposure time: 4 h Test atmosphere: dust/mist
Acute dermal toxicity	:	LD50 (Rabbit): > 2,000 mg/kg Assessment: The substance or mixture has no acute dermal toxicity

Mirtazapine Orally Disintegrating Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/01/2017
3.4	06/12/2017	50205-00008	Date of first issue: 01/23/2015

Magnesium stearate:

Acute oral toxicity : LD50 (Rat): > 2,500 mg/kg
Assessment: The substance or mixture has no acute oral toxicity

Skin corrosion/irritation

Not classified based on available information.

Ingredients:**Citric acid:**

Species: Rabbit
Method: OECD Test Guideline 404
Result: No skin irritation

Cellulose:

Result: No skin irritation
Remarks: Based on data from similar materials

Serious eye damage/eye irritation

Not classified based on available information.

Ingredients:**Citric acid:**

Species: Rabbit
Result: Irritation to eyes, reversing within 21 days
Method: OECD Test Guideline 405

Cellulose:

Result: No eye irritation
Remarks: Based on data from similar materials

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Ingredients:**Cellulose:**

Test Type: Local lymph node assay (LLNA)
Routes of exposure: Skin contact
Species: Mouse
Method: OECD Test Guideline 429
Result: negative
Remarks: Based on data from similar materials

Mirtazapine Orally Disintegrating Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/01/2017
3.4	06/12/2017	50205-00008	Date of first issue: 01/23/2015

Magnesium stearate:

Routes of exposure: Skin contact
Result: negative

Germ cell mutagenicity

Not classified based on available information.

Ingredients:**(+/-)-1,2,3,4,10,14b-hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

: Test Type: In vitro mammalian cell gene mutation test
Species: Chinese hamster lung cells
Result: negative

: Test Type: unscheduled DNA synthesis assay
Species: mammalian cells
Result: negative

: Test Type: sister chromatid exchange assay
Species: mammalian cells
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Rat
Cell type: Bone marrow
Application Route: Oral
Result: negative

Citric acid:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Rat
Application Route: Ingestion
Result: negative

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Remarks: Based on data from similar materials

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion

**Mirtazapine Orally Disintegrating Tablet For-
mulation**

Version 3.4	Revision Date: 06/12/2017	SDS Number: 50205-00008	Date of last issue: 05/01/2017 Date of first issue: 01/23/2015
----------------	------------------------------	----------------------------	---

Result: negative
Remarks: Based on data from similar materials

Carcinogenicity

Not classified based on available information.

Ingredients:**(+/-)-1,2,3,4,10,14b-hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Species: Mouse
Application Route: Oral
Exposure time: 18 month(s)
LOAEL: 200 mg/kg body weight
Result: equivocal
Target Organs: Liver

Species: Rat
Application Route: Oral
Exposure time: 2 Years
LOAEL: 20 mg/kg body weight
Result: equivocal
Target Organs: Liver, Thyroid

IARC

No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA

No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

NTP

No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Suspected of damaging fertility. Suspected of damaging the unborn child.

Ingredients:**(+/-)-1,2,3,4,10,14b-hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Oral
Fertility: LOAEL: 15 mg/kg body weight
Symptoms: Effect on estrous cycle Increase of early resorptions.
Result: Animal testing did not show any effects on fertility., Embryotoxic effects and adverse effects on the offspring were detected.

Effects on fetal development : Test Type: Development
Species: Rat
Application Route: Oral

Mirtazapine Orally Disintegrating Tablet Formulation

Version 3.4	Revision Date: 06/12/2017	SDS Number: 50205-00008	Date of last issue: 05/01/2017 Date of first issue: 01/23/2015
----------------	------------------------------	----------------------------	---

Developmental Toxicity: LOAEL: 100 mg/kg body weight
Result: Embryotoxic effects and adverse effects on the offspring were detected., No teratogenic effects.

Test Type: Development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: NOAEL: 40 mg/kg body weight
Result: No adverse effects., No teratogenic effects.

Reproductive toxicity - Assessment : Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse effects on development, based on animal experiments.

Citric acid:

Effects on fetal development : Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

May cause damage to organs (Nervous system) through prolonged or repeated exposure if swallowed.

Ingredients:

(+/-)-1,2,3,4,10,14b-hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Routes of exposure: Ingestion

Target Organs: Nervous system

Assessment: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Ingredients:**

(+/-)-1,2,3,4,10,14b-hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Species: Rat

LOAEL: 120 mg/kg

Application Route: Oral

Exposure time: 13 Weeks

Target Organs: Nervous system

Species: Dog

LOAEL: 15 mg/kg

Application Route: Oral

Exposure time: 52 Weeks

Target Organs: Nervous system

Symptoms: Tremors

Mirtazapine Orally Disintegrating Tablet Formulation

Version 3.4	Revision Date: 06/12/2017	SDS Number: 50205-00008	Date of last issue: 05/01/2017 Date of first issue: 01/23/2015
----------------	------------------------------	----------------------------	---

Species: Dog
LOAEL: 20 mg/kg
Application Route: Oral
Exposure time: 13 Weeks
Target Organs: Nervous system, Testes
Symptoms: Tremors

Citric acid:

Species: Rat
NOAEL: 4,000 mg/kg
LOAEL: 8,000 mg/kg
Application Route: Ingestion
Exposure time: 10 Days

Cellulose:

Species: Rat
NOAEL: > 5,000 mg/kg
Application Route: Ingestion
Exposure time: 90 Days
Remarks: Based on data from similar materials

Magnesium stearate:

Species: Rat
NOAEL: 5,000 mg/kg
Application Route: Ingestion
Exposure time: 3 Months

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Ingredients:****(+/-)-1,2,3,4,10,14b-hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Ingestion : Symptoms: Drowsiness, constipation, dry mouth, asthenia,
Dizziness, Disorientation

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Ingredients:****(+/-)-1,2,3,4,10,14b-hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 6.92 mg/l
Exposure time: 96 h
Method: FDA 4.11

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): 19.5 mg/l

Mirtazapine Orally Disintegrating Tablet For- mulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/01/2017
3.4	06/12/2017	50205-00008	Date of first issue: 01/23/2015

aquatic invertebrates	Exposure time: 48 h
Toxicity to algae	: EC50 (Pseudokirchneriella subcapitata (green algae)): 5.7 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 NOEC (Pseudokirchneriella subcapitata (green algae)): 3.2 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
Toxicity to fish (Chronic toxicity)	: NOEC (Pimephales promelas (fathead minnow)): 3.6 mg/l Exposure time: 31 d Method: OECD Test Guideline 210
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	: NOEC (Daphnia magna (Water flea)): 0.32 mg/l Exposure time: 21 d Method: OECD Test Guideline 211
Toxicity to microorganisms	: EC50 (Natural microorganism): > 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 NOEC (Natural microorganism): < 100 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209
Citric acid:	
Toxicity to fish	: LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): 1,535 mg/l Exposure time: 24 h
Cellulose:	
Toxicity to fish	: LC50 (Cyprinus carpio (Carp)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203 Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): > 100 mg/l Exposure time: 48 h Method: OECD Test Guideline 202 Remarks: Based on data from similar materials
Toxicity to algae	: EC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l Exposure time: 72 h Method: OECD Test Guideline 201

**Mirtazapine Orally Disintegrating Tablet For-
mulation**

Version 3.4	Revision Date: 06/12/2017	SDS Number: 50205-00008	Date of last issue: 05/01/2017 Date of first issue: 01/23/2015
----------------	------------------------------	----------------------------	---

Remarks: Based on data from similar materials

Persistence and degradability**Ingredients:****Citric acid:**

Biodegradability : Result: Readily biodegradable.
Biodegradation: 97 %
Exposure time: 28 d
Method: OECD Test Guideline 301B

Cellulose:

Biodegradability : Result: Readily biodegradable.

Magnesium stearate:

Biodegradability : Result: Not biodegradable.

Bioaccumulative potential**Ingredients:****(+/-)-1,2,3,4,10,14b-hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Bioaccumulation : Species: Oncorhynchus mykiss (rainbow trout)
Bioconcentration factor (BCF): 334
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 2.78

Citric acid:

Partition coefficient: n-octanol/water : log Pow: -1.61

Mobility in soil**Ingredients:****(+/-)-1,2,3,4,10,14b-hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Distribution among environmental compartments : log Koc: 4.48

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.

**Mirtazapine Orally Disintegrating Tablet For-
mulation**

Version	Revision Date:	SDS Number:	Date of last issue: 05/01/2017
3.4	06/12/2017	50205-00008	Date of first issue: 01/23/2015

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation**49 CFR**

Not regulated as a dangerous good

SECTION 15. REGULATORY INFORMATION**EPCRA - Emergency Planning and Community Right-to-Know****CERCLA Reportable Quantity**

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards

: Fire Hazard
Acute Health Hazard
Chronic Health Hazard

SARA 313

: This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations**Pennsylvania Right To Know**

D-mannitol	69-65-8
(+/-)-1,2,3,4,10,14b-hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine	85650-52-8
Polyvinyl pyrrolidone	9003-39-8

Mirtazapine Orally Disintegrating Tablet For- mulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/01/2017
3.4	06/12/2017	50205-00008	Date of first issue: 01/23/2015

Cellulose

9004-34-6

California Prop. 65

This product does not contain any chemicals known to the State of California to cause cancer, birth, or any other reproductive defects.

California List of Hazardous Substances

Polyvinyl pyrrolidone

9003-39-8

California Permissible Exposure Limits for Chemical Contaminants

Cellulose

9004-34-6

Magnesium stearate


557-04-0

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION**Further information****NFPA:****HMIS® IV:**

HEALTH	*	2
FLAMMABILITY		3
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
NIOSH REL	:	USA. NIOSH Recommended Exposure Limits
OSHA Z-1	:	USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
ACGIH / TWA	:	8-hour, time-weighted average
NIOSH REL / TWA	:	Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
OSHA Z-1 / TWA	:	8-hour time weighted average

**Mirtazapine Orally Disintegrating Tablet For-
mulation**

Version	Revision Date:	SDS Number:	Date of last issue: 05/01/2017
3.4	06/12/2017	50205-00008	Date of first issue: 01/23/2015

AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 06/12/2017

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8